Drug Profile
MG 1111
Alternative Names: BARYCELA; MG-1111Latest Information Update: 21 Feb 2023
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Varicella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Varicella zoster virus infections
Most Recent Events
- 19 Feb 2023 GC Biopharma plans to commercialize BARYCELA in global markets
- 23 Dec 2022 GC Biopharma plans a clinical trial for Varicella-zoster-virus-infections (In infants, In children, Prevention) in South Korea (SC) (NCT05664152)
- 31 Dec 2021 Launched for Varicella zoster virus infections (In children, In infants, Prevention) in South Korea (SC) in 2021 (GC Pharma's pipeline, July 2023)